

# INTERNATIONAL SEARCH REPORT

Inten. Appl. No  
PCT/GB 97/01165

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C12N15/62	C12N15/13	C07K16/30	C07K16/46	A61K47/48
	C07K19/00	C07K14/705	C12N9/64	C12N5/10	C12N1/21
	C12N5/20	//A01K67/027, A01H1/00			

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 633 029 A (CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD.) 11 January 1995 see claims ---	1-6, 12-15
X	BRITISH JOURNAL OF CANCER, vol. 72, no. 5, November 1995, BASINGSTOKE, GB, pages 1083-1088, XP002038652 D. BLKEY ET AL.: "Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs." see the whole document --- -/-	1-3,5,6, 12-15

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

22 August 1997

Date of mailing of the international search report

04.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

## INTERNATIONAL SEARCH REPORT

Intern. Appl. No.  
PCT/GB 97/01165

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 15341 A (CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD.) 8 June 1995  see example 4 see figure 3 see seq. id. nos 1, 2 ---	1-3, 5-10, 12-15
X	IMMUNOTECHNOLOGY, vol. 2, no. 1, 1996, AMSTERDAM, NL, pages 47-57, XP002038653 N. MICHAEL ET AL.: "In vitro and in vivo characterization of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein." see the whole document ---	1-3, 5-10, 12-15
X	WO 96 11013 A (IMMUNOMEDICS) 18 April 1996  see examples see claims ---	1-5, 8-10, 12-15
X	CANCER RESEARCH, vol. 55, no. 23 suppl., 1 December 1995, BALTIMORE, MD, USA, pages 5968S-5972S, XP002038654 S. LEUNG ET AL.: "Bacterial expression of a kemptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment." see abstract ---	1-5, 8-10, 12-15
X	WO 92 01059 A (CELLTECH LTD.) 23 January 1992  see examples see claims ---	1-4,8-10
X	CANCER RESEARCH, vol. 54, no. 7, 1 April 1994, BALTIMORE, MD, USA, pages 2151-2159, XP002038655 K. BOSSLET ET AL.: "Tumor-selective prodrug activation by fusion protein-mediated catalysis." see abstract ---	1-6, 12-15
A	WO 94 25585 A (GENPHARM INTERNATIONAL, INC.) 10 November 1994  see example 22 see claims -----	8-10,14

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 97/01165

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 15  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claim 15 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/GB 97/01165

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 633029 A	11-01-95	AT 119782 T CA 1336166 A DE 68921749 D DE 68921749 T EP 0414741 A WO 8910140 A JP 7324041 A JP 3503898 T US 5632990 A	15-04-95 04-07-95 20-04-95 13-07-95 06-03-91 02-11-89 12-12-95 29-08-91 27-05-97
WO 9515341 A	08-06-95	AU 1194795 A CA 2177584 A EP 0733072 A NZ 277057 A	19-06-95 08-06-95 25-09-96 27-07-97
WO 9611013 A	18-04-96	AU 3719695 A EP 0783313 A	02-05-96 16-07-97
WO 9201059 A	23-01-92	AT 137534 T AU 651984 B AU 8200591 A CA 2065325 A DE 69119211 D DE 69119211 T EP 0491031 A GB 2251859 A,B GB 2276169 A JP 5502587 T	15-05-96 11-08-94 04-02-92 06-01-92 05-06-96 19-12-96 24-06-92 22-07-92 21-09-94 13-05-93
WO 9425585 A	10-11-94	AU 3907895 A AU 6819494 A CA 2161351 A EP 0754225 A JP 8509612 T US 5625126 A JP 8140528 A	29-02-96 21-11-94 10-11-94 22-01-97 15-10-96 29-04-97 04-06-96